MediGene sells rosacea drug rights to Galderma
This article was originally published in Scrip
Executive Summary
MediGenehas sold the European rights to its rosacea treatment, Oracea (doxycycline), to the dermatological companyGalderma, just days after the European Commissiongave the all-clear to the product's approval in EU countries. The sale is part of MediGene's plan to move out of the dermatological arena and focus on cancer and immunology.